Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma

References

• GoldbergIRelationship between intraocular pressure and preservation of visual field in glaucomaSurv Ophthalmol200348Suppl 1S3S712852428
   PubMed Web of Science ®Google Scholar
• The Advanced Glaucoma Intervention Study (AGIS): 7The relationship between control of intraocular pressure and visual field deterioration. The AGIS InvestigatorsAm J Ophthalmol200013042944011024415
   PubMed Web of Science ®Google Scholar
• SoltauJBZimmermanTJChanging paradigms in the medical treatment of glaucomaSurv Ophthalmol200247Suppl 1S2S512204696
   PubMed Web of Science ®Google Scholar
• WeitzmanMCaprioliJTasmanWJaegerEAMedical Therapy of GlaucomaDuane’s OphthalmologyPhiladelphia, PALippincott Williams and Wilkins [CD-ROM]2002
   Google Scholar
• TammERittigMLutjen-DrecollEElectron microscopy and immunohistochemical studies of the intraocular pressure lowering effect of prostaglandin F2 alphaFortschr Ophthalmol1990876236292086407
   PubMedGoogle Scholar
• HedmanKWatsonPGAlmAThe effect of latanoprost on intraocular pressure during 2 years of treatmentSurv Ophthalmol200247Suppl 1S65S7612204702
   PubMed Web of Science ®Google Scholar
• EisenbergDLTorisCBCamrasCBBimatoprost and travoprost: a review of recent studies of two new glaucoma drugsSurv Ophthalmol200247Suppl 1S105S11512204706
   PubMed Web of Science ®Google Scholar
• NetlandPALandryTSullivanEKTravoprost Study GroupTravoprost compared with latanoprost and timolol in patients with openangle glaucoma or ocular hypertensionAm J Ophthalmol20013247248411589866
   PubMed Web of Science ®Google Scholar
• SaitoMTakanoRShiratoSEffects of latanoprost and unoprostone when used alone or in combination for open-angle glaucomaAm J Ophthalmol200113248548911589867
   PubMed Web of Science ®Google Scholar
• TakagiYNakajimaTShimazakiAPharmacological characteristics of AFP-168 (tafluprost), a new prostanoid receptor FP agonist, as an ocular hypotensive drugExp Eye Res20047876777615037111
   PubMed Web of Science ®Google Scholar
• AiharaMClinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertensionClin Ophthalmol2010416317020390038
   PubMedGoogle Scholar
• NoeckerRJHerrygersLAAnwaruddinRCorneal and conjunctival changes caused by commonly used glaucoma medicationsCornea20042349049615220734
   PubMed Web of Science ®Google Scholar
• ChaSHLeeJSOumBSKimCDCorneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitroClin Experiment Ophthalmol20043218018415068436
   PubMed Web of Science ®Google Scholar
• DebbaschCBrignoleFPisellaPJWarnetJMRatPBaudouinCQuaternary ammoniums and other preservatives’ contribution in oxidative stress and apoptosis on Chang conjunctival cellsInvest Ophthalmol Vis Sci20014264265211222522
   PubMed Web of Science ®Google Scholar
• IchijimaHPetrollWMJesterJVCavanaghHDConfocal microscopic studies of living rabbit cornea treated with benzalkonium chlorideCornea1992112212251587129
   PubMed Web of Science ®Google Scholar
• De Saint JeanMBrignoleFBringuierAFBauchetAFeldmannGBaudouinCEffects of benzalkonium chloride on growth and survival of Chang conjunctival cellsInvest Ophthalmol Vis Sci19994061963010067965
   PubMed Web of Science ®Google Scholar
• NoeckerREffects of common ophthalmic preservatives on ocular healthAdv Ther20011820521511783457
   PubMed Web of Science ®Google Scholar
• PisellaPJDebbaschCHamardPConjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro studyInvest Ophthalmol Vis Sci2004451360136815111589
   PubMed Web of Science ®Google Scholar
• IshibashiTYokoiNKinoshitaSComparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chlorideJ Glaucoma20031248649014646684
   PubMed Web of Science ®Google Scholar
• SamplesJRBinderPSNayakSThe effect of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cellsExp Eye Res1989491122759185
   PubMed Web of Science ®Google Scholar
• BaudouinCSide effects of antiglaucomatous drugs on the ocular surfaceCurr Opin Ophthalmol19967808610163327
   PubMedGoogle Scholar
• De Saint JeanMDebbaschCBrignoleFRatPWarnetJMBaudouinCToxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cellsCurr Eye Res200020859410617908
   PubMed Web of Science ®Google Scholar
• HongSLeeCSSeoKYSeongGJHongYJEffects of topical antiglaucoma application on conjunctival impression cytology specimensAm J Ophthalmol200614218518616815281
   PubMed Web of Science ®Google Scholar
• BaudouinCHamardPLiangHCreuzot-GarcherCBensoussanLBrignoleFConjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long termOphthalmology20041112186219215582072
   PubMed Web of Science ®Google Scholar
• MajumdarSHippalgaonkarKRepkaMAEffect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit corneaInt J Pharm200834817517817897799
   PubMed Web of Science ®Google Scholar
• LewisRAKatzGJWeissMJTravoprost BAC-free Study GroupTravoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacyJ Glaucoma2007169810317224758
   PubMed Web of Science ®Google Scholar
• EastyDLNemeth-WasmerGVounatsosJPComparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patientsBr J Ophthalmol20069057457816622086
   PubMed Web of Science ®Google Scholar
• PellinenPLokkilaJCorneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprostOphthalmic Res20094111812219147999
   PubMed Web of Science ®Google Scholar
• CazevieilleCMullerAMeynierFDutraitNBonneCProtection by prostaglandins from glutamate toxicity in cortical neuronsNeurochem Int1994243953987914788
   PubMed Web of Science ®Google Scholar
• KanamoriANakaMFukudaMNakamuraMNegiATafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivoGraefes Arch Clin Exp Ophthalmol20092471353136019551401
   PubMed Web of Science ®Google Scholar
• KanamoriANakaMFukudaMNakamuraMNegiALatanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivoExp Eye Res20098853554119084521
   PubMed Web of Science ®Google Scholar
• KudoHNakazawaTShimuraMNeuroprotective effect of latanoprost on rat retinal ganglion cellsGraefes Arch Clin Exp Ophthalmol20062441003100916411104
   PubMed Web of Science ®Google Scholar
• NakanishiYNakamuraMMukunoHKanamoriASeigelGMNegiALatanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogenactivated protein kinaseExp Eye Res2006831108111716839545
   PubMed Web of Science ®Google Scholar
• BullNDJohnsonTVWelsaparGDeKorverNWTomarevSIMartinKRUse of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapiesInvest Ophthalmol Vis Sci2011523309332021345987
   PubMed Web of Science ®Google Scholar
• FukanoYKawazuKAkaishiTBezwadaPPellinenPMetabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeysJ Ocul Pharmacol Ther20112725125921491995
   PubMed Web of Science ®Google Scholar
• FukanoYKawazuKDisposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to ratsDrug Metab Dispos2009371622163419477946
   PubMed Web of Science ®Google Scholar
• UusitaloHKaarnirantaKRopoAPharmacokinetics, efficacy and safety of preserved and preservative-free tafluprost in healthy volunteersActa Ophthalmol Suppl (Oxf)2008242S7S13
   PubMedGoogle Scholar
• KurashimaHAsaiYAiharaMIshidaNNakamuraMAraieMOcular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeysJ Glaucoma20122112312821423041
   PubMed Web of Science ®Google Scholar
• OtaTAiharaMSaekiTThe IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient miceBr J Ophthalmol20079167367617124244
   PubMed Web of Science ®Google Scholar
• TraversoCERopoAPapadiaMA Phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprostJ Ocul Pharmacol Ther2010269710420148656
   PubMed Web of Science ®Google Scholar
• UusitaloHPillunatLERopoAEfficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III studyActa Ophthalmol201088121920420586
   PubMed Web of Science ®Google Scholar
• SchnoberDHofmannGMaierHScherzerMLOgundeleABJasekMCDiurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertensionClin Ophthalmol201081459146321191441
   PubMedGoogle Scholar
• IzumiNNagaokaTSatoEShort-term effects of topical tafluprost on retinal blood flow in catsJ Ocul Pharmacol Ther20082421526
   Web of Science ®Google Scholar
• AkaishiTKurashimaHOdani-KawabataNIshidaNNakamuraMEffects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbitsJ Ocul Pharmacol Ther20102618118620334534
   PubMed Web of Science ®Google Scholar
• KurashimaHWatabeHSatoNAbeSIshidaNYoshitomiTEffects of prostaglandin F(2α) analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprostExp Eye Res20109185385920868682
   PubMed Web of Science ®Google Scholar
• UusitaloHChenEPfeifferNSwitching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medicationActa Ophthalmol20108832933620546237
   PubMed Web of Science ®Google Scholar
• LiangHBaudouinCPaulyABrignole-BaudouinFConjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chlorideBr J Ophthalmol2008921275128218723745
   PubMed Web of Science ®Google Scholar